Provided by Tiger Trade Technology Pte. Ltd.

PDS Biotechnology Corporation

0.5414
-0.0987-15.42%
Post-market: 0.59980.0584+10.79%19:59 EDT
Volume:989.25K
Turnover:563.07K
Market Cap:28.57M
PE:-0.67
High:0.6400
Open:0.6400
Low:0.5237
Close:0.6401
52wk High:1.92
52wk Low:0.5225
Shares:52.77M
Float Shares:51.41M
Volume Ratio:1.67
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8140
EPS(LYR):-1.0318
ROE:-221.81%
ROA:-46.22%
PB:3.02
PE(LYR):-0.52

Loading ...

PDS Biotechnology Corp expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
Mar 27

Updated PDS-VIS

Reuters
·
Mar 27

PDS Biotech to Host Conference Call and Webcast for Q4 and Full-Year 2025 Results

Reuters
·
Mar 25

PDS Biotechnology Corp expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
Mar 23

CitiFirst Instalment MINIs Issue 5 March 2026 PDS-CTW

Reuters
·
Mar 04

Nasdaq flags PDS Biotechnology for sub-$1 minimum bid price deficiency

Reuters
·
Mar 04

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB), Integer Holdings (ITGR) and Tonix Pharma (TNXP)

TIPRANKS
·
Feb 23

PDS Biotech Adds PFS Interim Primary Endpoint to Phase 3 VERSATILE-003 Trial for PDS0101 in HPV16-Positive Head and Neck Cancer

Reuters
·
Feb 20

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 Versatile-003 Trial Incorporating Progression Free Survival (Pfs) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

THOMSON REUTERS
·
Feb 20

PDS Biotechnology Corp - Median Overall Survival Remains Primary Endpoint for Full Approval

THOMSON REUTERS
·
Feb 20

PDS Biotechnology Corp - Amendment Includes Pfs for Potential Accelerated Approval

THOMSON REUTERS
·
Feb 20

Update of Information - Fee and Costs Disclosure in the PDS-GSC

Reuters
·
Jan 30

PDS Biotech Reports Promising Phase 2 Results for PDS01ADC in Metastatic Prostate Cancer

Reuters
·
Jan 28

PDS Biotechnology Receives Notice of Allowance for New U.S. Patent Covering PDS0101 Technology

Reuters
·
Jan 22

BUZZ-PDS Biotech rises as it seeks faster FDA nod for cancer drug

Reuters
·
Jan 09

BRIEF-Pds Biotech Announces FDA Alignment On Use Of Progression Free Survival (Pfs) As Primary Endpoint

Reuters
·
Jan 09

PDS Biotech Submits Amended Phase 3 Trial Protocol for FDA Review

Reuters
·
Jan 09

PDS Biotechnology Corp - Median Overall Survival Remains Primary Endpoint for Full Approval

THOMSON REUTERS
·
Jan 09

PDS Biotech Announces FDA Alignment on Use of Progression Free Survival (Pfs) as Primary Endpoint

THOMSON REUTERS
·
Jan 09

MGOC Replacement PDS-MGO

Reuters
·
Dec 17, 2025